Deals17 Nov 2025, 03:46 pm
AstraZeneca Pharma India and Sun Pharma Partner to Help Patients Living with Hyperkalaemia in India
AI Summary
AstraZeneca Pharma India Limited (AstraZeneca) and Sun Pharmaceutical Industries Limited (Sun Pharma) have entered into a Distribution Services Agreement for the distribution of Sodium Zirconium Cyclosilicate (SZC) powder for oral suspension 5 g in India. AstraZeneca will market SZC as Lokelma®, while Sun Pharma will promote and distribute the therapy as Gimliand®. This partnership aims to further accelerate the availability of SZC, an innovative and highly effective treatment for Hyperkalaemia, to more patients across India.
Key Highlights
- AstraZeneca and Sun Pharma enter into a Distribution Services Agreement for the distribution of Sodium Zirconium Cyclosilicate (SZC) in India.
- AstraZeneca will market SZC as Lokelma®, while Sun Pharma will promote and distribute the therapy as Gimliand®.
- This partnership aims to accelerate the availability of SZC, an innovative and highly effective treatment for Hyperkalaemia, to more patients across India.
- Sun Pharma is the largest pharmaceutical company in India with an 8.3% market share and ranks No. 1 in prescriptions across 13 different doctor categories.
- This strategic step is a significant move in improving the management of Hyperkalaemia in India; promising enhanced availability to a crucial treatment and ultimately contributing to better patient outcomes nationwide.